ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Ovid Therapeutics Inc

Ovid Therapeutics Inc (OVID)

1.14
-0.01
(-0.87%)
Closed October 14 4:00PM
1.14
0.00
( 0.00% )
Pre Market: 8:27AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.14
Bid
1.08
Ask
1.18
Volume
1
0.00 Day's Range 0.00
0.68 52 Week Range 4.10
Market Cap
Previous Close
1.14
Open
-
Last Trade
1
@
1.18
Last Trade Time
08:21:51
Financial Volume
-
VWAP
-
Average Volume (3m)
183,011
Shares Outstanding
70,971,577
Dividend Yield
-
PE Ratio
-1.55
Earnings Per Share (EPS)
-0.74
Revenue
392k
Net Profit
-52.34M

About Ovid Therapeutics Inc

Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines for patients and families living who are suffering from epilepsies, seizure-related disorders, and neurological disorders. It is targeting disorders such as intellectual disability, ... Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines for patients and families living who are suffering from epilepsies, seizure-related disorders, and neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patient's life. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Ovid Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OVID. The last closing price for Ovid Therapeutics was $1.14. Over the last year, Ovid Therapeutics shares have traded in a share price range of $ 0.68 to $ 4.10.

Ovid Therapeutics currently has 70,971,577 shares outstanding. The market capitalization of Ovid Therapeutics is $80.91 million. Ovid Therapeutics has a price to earnings ratio (PE ratio) of -1.55.

OVID Latest News

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes...

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain...

Ovid Therapeutics to Present at Upcoming September Investor Conferences

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain...

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded Scientific Advisory Board under the leadership of...

Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.03-2.56410256411.171.191.031104711.12096851CS
40.010.8849557522121.131.191.031201671.12776805CS
120.19.615384615381.041.30.81830111.09569927CS
26-2.07-64.48598130843.213.450.685309211.03207039CS
52-2.52-68.85245901643.664.10.683544761.57431544CS
156-2.51-68.76712328773.654.13890.682267012.23562978CS
260-1.28-52.89256198352.4210.450.686556013.86666866CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZPTAZapata Computing Holdings Inc
$ 0.1518
(97.14%)
81.86M
DBGIDigital Brands Group Inc
$ 0.30
(87.73%)
24.89M
BNZIBanzai International Inc
$ 5.67
(53.24%)
6.08M
BDSXBiodesix Inc
$ 2.37
(48.13%)
221
GRTSGritstone bio Inc
$ 0.0761
(40.93%)
105.27M
QRTEBQurate Retail Inc
$ 2.14
(-44.13%)
159
NTBLNotable Labs Ltd
$ 0.25
(-37.50%)
456.27k
FUNDSprott Focus Trust Inc
$ 6.01
(-22.25%)
64
STIMNeuronetics Inc
$ 0.713
(-19.89%)
2
PEGYPineapple Energy Inc
$ 0.10
(-19.87%)
3.3M
GRTSGritstone bio Inc
$ 0.0761
(40.93%)
105.27M
ZPTAZapata Computing Holdings Inc
$ 0.1518
(97.14%)
81.86M
DBGIDigital Brands Group Inc
$ 0.30
(87.73%)
24.89M
LIPOLipella Pharmaceuticals Inc
$ 0.4778
(16.91%)
17.85M
ENVBEnveric Biosciences Inc
$ 0.4388
(6.50%)
13.2M

OVID Discussion

View Posts
Monksdream Monksdream 1 month ago
OVID under $2
πŸ‘οΈ0
glenn1919 glenn1919 2 months ago
OVID................................https://stockcharts.com/h-sc/ui?s=OVID&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
OVID under $2
πŸ‘οΈ0
RNsidersbuying RNsidersbuying 3 years ago
OVID 3.48 - setup for a freeroll???

$3 netcash-per-share?

Takeda, going forward, to incur all research expenses?

Two Phase-3-commencement announcement catalysts upcoming in 2021?

Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.

https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2
πŸ‘οΈ0
MfridgeV2 MfridgeV2 4 years ago
Oh, the boredom that 6 buy ratings gets you. Poor OVID board.

Slow climb to earnings in a couple weeks.
πŸ‘οΈ0
MfridgeV2 MfridgeV2 4 years ago
Held up well during a blood couple of days. Earnings coming up in two weeks.

πŸ‘οΈ0
MfridgeV2 MfridgeV2 4 years ago
Up a bit PM... not bad at all after the jump.
πŸ‘οΈ0
Mamameloconto Mamameloconto 4 years ago
Someone just bought 200k share block not long ago we know it’s worth more way more
πŸ‘οΈ0
MfridgeV2 MfridgeV2 4 years ago
Holding very well on an ugly day- love it!
πŸ‘οΈ0
Mamameloconto Mamameloconto 4 years ago
15 in 3 months I’ll wait with 300m plus cash and milestones kicking in
πŸ‘οΈ0
MfridgeV2 MfridgeV2 4 years ago
Should be a good month for OVID. ;)
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $OVID Video Chart 03-03-2021 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Actualfactual Actualfactual 4 years ago
Curling back up..let’s best that intraday high of 4.75 going into power hour!
πŸ‘οΈ0
Mamameloconto Mamameloconto 4 years ago
Looks like a 20 dollar stock soon manipulation at its finest shakeout on bs trades for the big dogs lol this stock worth 8 minimum with that news today now I’m holding for a month to 20 obvious big boys want in cheap
πŸ‘οΈ0
AlphaStockNews AlphaStockNews 4 years ago
$OVID is screaming for the top after the company announced that Takeda has purchased the rights to a key candidate. https://cnafinance.com/ovid-stock-ovid-therapeutics-climbs-on-takeda-agreement/
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 years ago
$OVID
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 years ago
Nice, $3s very possible today .
πŸ‘οΈ0
stoner422 stoner422 4 years ago
BCLI, I made out so far on selling $5 puts for the 18th, have had those awhile and will probably buy them back this week if the stock drops a little. OVID on the other hand my 12/11 $5 puts were already assigned. Not looking good for those, I need a $4 share price by next Friday to break even. BCLI has been a much better play.
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 years ago
The company still at strong buy, by 7 analysts .
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 years ago
I’ve seen some play like this and they had good news after the bad news and it went back up right away, I’m not saying it will happen here, but I think people over react to the news today, should bounce some tomorrow imo, market cap over $420M !!
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 years ago
That’s good enough for me .
πŸ‘οΈ0
Market_scab Market_scab 4 years ago
Just like BCLI. you will get a 20% jump between now and friday. This always happens, the selling is always overdone on these biotechs
πŸ‘οΈ0
Market_scab Market_scab 4 years ago
way oversold. They are not a one trick pony
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 years ago
$OVID I’m in should have a nice bounce of this level .
πŸ‘οΈ0
saj saj 4 years ago
big dip in ah's
πŸ‘οΈ0
saj saj 4 years ago
3.28 in ah's
πŸ‘οΈ0
Munchy Munchy 4 years ago
This could turn out to be
the best buying day we've
seen a quite a while.
πŸ‘οΈ0
Munchy Munchy 4 years ago
I managed to get 500 shares
at $6.50. Just missed getting
500 at $6.40. Oh well.
πŸ‘οΈ0
Munchy Munchy 4 years ago
I'll try to buy
before 2PM today.
πŸ‘οΈ0
Munchy Munchy 4 years ago
What can we expect from the
presentation tomorrow?
πŸ‘οΈ0
Nfixus Nfixus 4 years ago
new article out today at PSN:

https://pennystocks.news/why-ovid-therapeutics-is-on-the-radar-of-many-farmaceutical-investors-ovid/
πŸ‘οΈ0
dannyzee84 dannyzee84 4 years ago
I’m here as well.. wondering when we’ll get that stage 3 news.. also, I see a 100k share wall at 8.40?
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $OVID Video Chart 06-18-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Munchy Munchy 4 years ago
Am I the only one making
big money on this stock?
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $OVID Video Chart 12-17-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $OVID Video Chart 11-29-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $OVID Video Chart 11-27-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
stockguard stockguard 5 years ago
OVID THERAPEUTICS (NASDAQ:OVID) PRICE TARGET AND CONSENSUS RATING
7 Wall Street analysts have issued ratings and price targets for Ovid Therapeutics in the last 12 months. Their average twelve-month price target is $14.00, suggesting that the stock has a possible upside of 460.00%. The high price target for OVID is $27.00 and the low price target for OVID is $10.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
https://www.marketbeat.com/stocks/NASDAQ/OVID/price-target/
πŸ‘οΈ0
stockguard stockguard 5 years ago
Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020

https://seekingalpha.com/pr/17683312-ovid-therapeutics-announces-senior-management-promotions-preparation-multiple-data-readouts
πŸ‘οΈ0
stockguard stockguard 5 years ago
1- Price action relative to the biotech sector and signs of accumulation. The stock made a nearly 5% move yesterday on good volume, despite the XBI closing negative.

2. I reviewed the company's updated presentation. The last time I'd looked, they'd been guiding for Fragile X readout in Q4 or close to year end (perhaps the riskiest but least impactful of the 4 expected readouts over the next year). However, now they are guiding for it in early 2020 and I remind members that the ARCADE readout for soticlestat in CDKL5 Deficiency Disorder / Dup15q Syndrome is expected in Q1. I have higher conviction for this second readout, considering promising results we reviewed previously for the ENDYMION open label extension trial.

Given this change, to my eyes it makes it less feasible to wait for the Fragile X readout to get in prior to ARCADE. As preclinical rationale for OV101 appears intriguing and data in FXS mice has shown normalization of certain aspects of Fragile X (anxiety, irritability, repetitive behaviors, hyperactivity), I don't mind being exposed to both readouts (with Angelman to follow midyear).

Market capitalization of around $125 million seems quite reasonable relative to substantial market opportunities being targeted and multi-faceted neurology pipeline (cash position boosted by secondary as well). This is primarily a catalyst idea, as several data events loom in the near to medium term (OV101 in Fragile X and Angelman, soticlestat in phase 2 ARCADE study and phase 2 ELEKTRA trial). OV101 is the only drug in development for Angelman Syndrome, and management appears to have much confidence in achieving the same CGI-I endpoint as the prior mid-stage study (FDA gave them green light to file for registration if they can do so). Soticlestat, 50-50 partnered with Takeda, has a unique mechanism of action that not only crushes seizures but also potentially heals the brain. The asset is both first-in-class and only-in-class, is targeting a large opportunity in rare epilepsies, and has shown impressive seizure reduction in prior trials (caveat for low N). ENDYMION extension data provided another element of derisking as a group of incredibly difficult to treat patients experienced increased seizure reduction with prolonged treatment. See my September article. Time Frame For Upside = 6 to 12 months as multiple data readouts come to pass (Catalyst Idea).
πŸ‘οΈ0
stockguard stockguard 5 years ago
Soticlestat Shows Promise for Developmental Epileptic Encephalopathies

Soticlestat Shows Promise for Developmental Epileptic Encephalopathies
The director of pediatric epilepsy at Northeast Regional Epilepsy Group and co-director of epileptology at Hackensack University Medical Center spoke about soticlestat and what can be gleaned from data thus far.
By: Matt Hoffman


Published: October 17, 2019
Dr Eric SegalEric Segal, MDRecently, Ovid Therapeutics announced that its phase 2 open-label extension study of soticlestat produced initial positive results, with data suggesting that the therapy is effective over the long-term in treating patients with rare developmental epileptic encephalopathies.

Ultimately, the highly selective first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H) was associated with seizure reduction over 48 weeks in a small cohort of 7 patients. The median seizure frequency reductions were 84% after 25 to 36 weeks (n = 6) and 90% after 37 to 48 weeks (n = 4) of treatment, with 2 patients experiencing seizure-free runs of 264 and 150 consecutive days, respectively. Additionally, the safety and tolerability of soticlestat, previously known as OV935/TAK935, was consistent with the observations from the phase 1b/2a trial.

Amit Rakhit, MD, MBA, Chief Medical Officer, Head of Research & Development, Ovid, said in a statement that the clinical development program of soticlestat in developmental epileptic encephalopathies is expected to read out data from the ARCADE and ELEKTRA studies in 2020.

To learn more about soticlestat and the latest data, NeurologyLive spoke with Eric Segal, MD, director, pediatric epilepsy, Northeast Regional Epilepsy Group, co-director, epileptology, Hackensack Meridian Health, and assistant professor of pediatrics and neurology, Hackensack Meridian School of Medicine. Segal, a trial investigator for soticlestat, provided insight into the clinical takeaways and the potential of the therapy.
NeurologyLive: What does the clinician community need to know about these data and about soticlestat in general?
Eric Segal, MD: The preliminary data that we've seen thus far is very exciting for a first-in-class mechanism. We have pretty significant positive efficacy results in a small group of adult patients who typically have pretty severe epilepsies and it was well tolerated. I think all those pieces are very interesting.

Obviously, we need to see how this therapy works in larger groups of patients. That's going to be the next big thing. What I found to be the most interesting about the data was not only the significant median seizure reduction but also how seizure reduction was sustained and improved the longer the patients took on the medication. A lot of times when we look at open-label extensions, we tend to see a significant drop out in the number of patients. There's a small number of patients to start with, but the majority of those patients stayed in the study and had improvements in seizure frequency going from week 1 through week 36. That is very unique.
Are there any other specific datapoints that make this therapy stand out or make this therapy unique in this space?
There are a few things. One is that the sustained efficacy in this group of patients is significant. Especially in a group of patients with epileptic encephalopathies who tend to try or have used, and unfortunately have failed, some of our most effective medications that are available. To have such a high seizure reduction rate that is sustained in a group of people that have failed what we would think of as our strongest or most efficacious medications, I think that is very significant.
Is there a particular rare epilepsy or subgroup in which soticlestat has significant potential?
The therapy is underway in study for Lennox-Gastaut syndrome and Dravet syndrome. I would say that a lot of these rare disorders can be very difficult to treat in clinical practice. I think for most clinicians, of the potential indicated epilepsies, Lennox-Gastaut syndrome is probably going to be where you find the greatest number of patients with a great need, and it's exciting to see that this therapy is being considered for that. I'm really interested in seeing that in all the genetic epilepsies that that's being tested in. But especially in Lennox-Gastaut, given that we have such a large LGS community of patients that definitely need better therapies than are what are currently available.

Transcript edited for clarity.

https://www.neurologylive.com/clinical-focus/soticlestat-shows-promise-for-developmental-epileptic-encephalopathies
πŸ‘οΈ0
dirtydozen911 dirtydozen911 5 years ago
dumping shares today.......it will take a while for this unknown ticker, to absorb the 32 million offering from last week

buy /sell volume.....147k / 264k...at 3 pm.......down 11% on a decent market.......I think this has a way to go.......O S will go from 40 mill to at least 55mill

think I`ll check back in a few days......was trading $1.70`s around labor day........this will keep going down the stairs for a while.......glta
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $OVID Video Chart 10-04-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
dirtydozen911 dirtydozen911 5 years ago
been watching this since they ran it up a few weeks ago.......didn`t buy ......could smell an OFFERING

WE GOT IT TODAY add at least another 13 million to the 40 mill O S ........nice 33% increase in share count...good job

they , like all the bio`s, have a few things in the pipe

this 27% pull back is not nearly enough, based on the new O S structure...........this belongs back at $2.....glta
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock